Q&A with Ul­tragenyx CEO: Time to in­crease the use of ac­cel­er­at­ed ap­provals for rare dis­ease drugs

Emil Kakkis, CEO of the rare dis­ease drug­mak­er Ul­tragenyx Phar­ma­ceu­ti­cals, sat down with End­points News to­day in Wash­ing­ton, DC to dis­cuss in­dus­try’s more re­cent strug­gles …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER